PDE4A and chronic obstructive pulmonary disease: Numerous selective PDE4 inhibitors have been patented and some of them have been evaluated in clinical trials, including diseases, such as asthma, COPD, atopic dermatitis, rheumatoid arthritis, and psoriasis/psoriasis arthritis.